Kornimate/medical-research-clean huggingface dataset:
study of the use of [18f]-dopa in hyperinsulinemic hypoglycemia

Conditions: Hyperinsulinemic Hypoglycemia, Persistent; Congenital Hyperinsulinism; Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)

Summary: the primary objective of this study is to evaluate the utility of \[18f\]-dopa pet to provide improved presurgical planning and distinguish between focal and diffuse forms of hi. the investigators will perform descriptive analysis, relying on visual analysis to diagnose and localize a focal lesion. our findings will be compared to surgical histopathology to determine sensitivity and specificity or this technique. the investigators will also track patient surgical outcomes, specifically whether the patient is surgically "cured" or still requires medical management to control residual hypoglycemia.

hyperinsulinemic hypoglycemia is caused by low glucose due to excessive insulin secretion and remains difficult to treat because of the requirement for extensive amounts of glucose and the lack of effective long-term medical therapy. correct diagnosis, localization, and limited excision of the focal lesion will result in a complete cure of the patient. in contrast, medically unresponsive diffuse disease requires a near total pancreatectomy, greatly increasing the risk of future diabetes mellitus. fortunately, \[18f\]-dopa pet has been shown to be a useful noninvasive imaging method for distinguishing between focal and diffuse forms of hyperinsulinemic hypoglycemia. in this study, the investigators seek to validate the effectiveness of using pet/mr and pet/ct with f-dopa to accurately and reliably detect and localize disease.

Eligibility criteria:
inclusion criteria: * all patients clinically diagnosed with hyperinsulinemia of any age * patients in need of pet scan * patients that require sedation * patients that do not require sedation exclusion criteria: subjects presenting with any of the following will not be included in the study: * patients without hyperinsulinemia * patients who are or may be pregnant * serious intercurrent medical illness other than hypoglycemia that precludes having the scan either because of patient instability or concerns about potential toxicity. * patient's requiring emergency surgical intervention that would be inappropriately delayed by \[18f\]-dopa pet imaging.

Keywords: hyperinsulinemic hypoglycemia pet/ct pet/mri [18f]-dopa pet/mr congenital hyperinsulinism
a prospective imaging study of the integrated truebeam-hypersight cbct system

Conditions: Head and Neck Cancer; Thoracic Cancer; Abdominal Cancer; Pelvic Cancer

Summary: cone beam computed tomography (cbct) images are routinely used in radiation treatment delivery workflows to align patients with the treatment beam. conventional cbct image quality is sufficient for this task but not good enough for other radiotherapy-related tasks, such as contouring anatomical structures and calculating radiation dose distributions. hypersight is a new cbct imaging system manufactured by varian medical systems. the purpose of this study is to evaluate the integration of the hypersight imaging system with varian's truebeam radiotherapy system, a linear accelerator with a c-arm gantry that rotates about the patient to delivery radiation to the target malignancy. hypersight cbct images will be acquired prospectively from patients who are receiving radiation treatment. the hypersight/truebeam system will be used for imaging only; patients receive their radiation treatment on cleared devices and no aspect of their treatment is affected by participation in the study. hypersight images collected during the study will be evaluated for quality and utility and compared to conventional cbct images as well as fan beam ct images used for treatment planning.


Eligibility criteria:
inclusion criteria: 1. patient is scheduled to receive radiation therapy to one of the following anatomical sites: head and neck/brain, thorax, abdomen, pelvis. 2. patient is at least 18 years of age. 3. if the patient will be receiving iv contrast on study, patient must have adequate renal function as defined by an estimated glomerular filtration rate (egfr) of \>30. note: if no iv contrast will be administered on study, patient may enroll without creatinine level documented. contrast eligibility will be determined as per appendix a. 4. if the patient is a woman of childbearing potential, patient must have a negative pregnancy test within 30 days of enrollment and prior to any study imaging. contraceptive use is not an adequate documentation of no chance of pregnancy. exclusion criteria: 1. patient is unwilling or unable to sign an irb-approved written informed consent document. 2. patient is part of a vulnerable population (per iso 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response").
prognosis of patients who presented with a state of extreme agitation.

Conditions: Emergence Delirium

Summary: the main objective is to assess the 6-month prognosis of patients who presented with extreme agitation in the emergency room. the primary endpoint is the 6-month mortality of agitated patients.

emergency services are confronted with emergency situations characterized by patients who are victims of significant agitation, in particular states of extreme agitation "excited delirium syndrome", which is constantly increasing and which seems to be associated with morbidity and mortality not negligible. patients meeting the inclusion and non-inclusion criteria are included on admission to the emergency room. an evaluation at h1 and at the end of hospitalization is carried out. the patient is contacted by telephone at m1, m3 and m6. the inclusion period is 24 months the duration of participation (treatment + follow-up) is 6 months the total duration is 30 months. the research is multicentric and national with the participation of 8 centres.

Eligibility criteria:
inclusion criteria: * agitated patient with the presence of three major criteria, namely, * restlessness * insensitivity to pain * tachypnea (fr\>20) and the presence of a minor criterion among * sweating * skin hyperthermia * non-compliance with law enforcement * tirelessness * unusual strength * inappropriate clothing, nudity exclusion criteria: * patient age \< 18 years * head trauma * pregnancy * detained * other obvious causes of pain leading to restlessness (renal colic, migraines, etc.)
inybi tool in chronic neck pain

Conditions: Neck Pain

Summary: objectives: to evaluate the clinical efficacy of using a manual inhibition technique for the suboccipital muscles compared with the use of the so-called inybi tool in individuals with chronic non-specific neck pain, and the compare the results of using both approaches on pain relief, cervical range of motion neck and vertical maximum mouth opening. design: quantitative, experimental, longitudinal, prospective, and double blinded study. subjects: patients between 18 and 40 years, with chronic non-specific neck pain of at least 3 months of evolution. methods: the experimental group will undergo a 5 minutes intervention for the suboccipital muscles using the inybi tool. the control group will receive a 5 minutes of treatment involving the suboccipital muscles manual inhibition technique.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of non-specific mechanical neck pain. * pain of more than 3 months of duration. * pain between the occiput and the third dorsal vertebra. * willingness to participate in the treatment and in the follow-up measurements * neck pain reproduced by neck movements or palpation exclusion criteria: * cognitive impairment or inability to communicate. * having received manual therapy in the last two months before recruitment. * having received anti-inflammatory treatment, antidepressants or muscle relaxants in the last 72 hours. * any contraindication to treatment or evaluation procedures. * diagnosis of systemic diseases * diagnosis of fibromyalgia * pregnancy * signs of spinal nerve root compression * previous whiplash * any diagnosed possible cause for their neck pain (infection, cancer, spinal stenosis)

Keywords: neck pain randomized control trial manual therapy physical therapy suboccipital inhibition
a substance use adaptation of fathering through change

Conditions: Parenting; Substance Use

Summary: this study is a randomized control trial of the fathering through change intervention, delivered via text messaging, to fathers in recovery for substance use disorders.


Eligibility criteria:
inclusion criteria: * identify as being in recovery * abstinent from illicit substances for at least 1 day and less than one year at time of enrollment * parenting responsibilities for a child between the ages of 3-16 * spend at least 2 hours per week with child between ages of 3-16 * english speaking exclusion criteria: -
discussion on pulse diagnosis and heart rhythm variability of patients with chronic insomnia

Conditions: Heart Rate Variability; Insomnia Chronic

Summary: discuss the objective assessment of patients with insomnia by pulse diagnosis, and measure by subjective questionnaire and physiological instruments.

in taiwan, insomnia is a prevalent illness. clinical symptoms of sleep disturbances are rather typical now that the epidemic has taken hold. pulse diagnosis is an important diagnostic method for insomnia in traditional chinese medicine(tcm). tcm pulse diagnosis is not yet a widely used clinical diagnostic method for illnesses, nevertheless. clinical use and teaching should benefit greatly if pulse diagnosis or learning can be made more objective or data-based.

Eligibility criteria:
inclusion criteria: * aged 40-60 years * complaints of insomnia symptoms in the past month that lasted for at least one week, such as difficulty falling asleep, waking up easily in the middle of the night, unable to fall asleep after waking up, still not getting enough sleep after waking up in the morning * the score of sleep disorder on the pittsburgh sleep quality scale was more than 5 points exclusion criteria: * history of psychiatric disorders * history of sleep apnea or nocturnal myoclonus * center or neurodegenerative disease * cancer * melatonin or sleeping pills use in the past month

Keywords: insomnia pulse heart rate variability
efficacy of education versus education plus prescribed fluid intake on hydration status in high school athletes

Conditions: Dehydration

Summary: sports science testing by investigators at gatorade sports science institute has revealed that many athletes arrive at practice with a high urine specific gravity indicating they are hypohydrated. though the data showed that most athletes don't lose more than 2% of their body weight in sweat during a training session, it is not known what the cumulative effects of living and training in a hot environment are over the course of a week. previous research has indicated that prescribing fluid intake is more effective than education in improving drinking behavior during exercise. no studies to date have compared the impact of fluid intake prescription versus education in adolescent boys and girls playing outdoor and indoor sports. comparing sexes and training environment may provide more clarity around potential barriers and challenges to proper hydration for each environment.

this study will implement a parallel design with 4 sports team groups: 1) indoor girls, 2) indoor boys, 3) outdoor girls, and 4) outdoor boys. each group of 36 per groups will be randomized into 1 of 3 conditions: 1) control (no intervention), 2) hydration education intervention, 3) prescribed hydration and education intervention. athletes will be observed for three practices per week for 2 weeks. practices are separated by at least 48 hours.

Eligibility criteria:
inclusion criteria: 1. females and males between the ages of 13-19 years old 2. non-smoker 3. currently enrolled in the img sports program 4. able to give verbal and written informed consent for participation as well as obtain parental consent if \<18 years of age 5. must be fluent in english reading, writing, and speaking 6. parental permission exclusion criteria: 1. expulsion from school for any reason 2. leaving the img sports program 3. pregnant or planning to become pregnant 4. illness or injury that impacts sport participation or fluid balance 5. taking any medication that impacts fluid balance 6. participation in a clinical trial within past 30 days 7. participation in any pepsico trial within past 6 months 8. any condition the study investigator believes would interfere with eligibility following the study protocol, effect the study results, or put the subject at undue risk

Keywords: hydration hypohydration adolescent athlete sports exercise behavior education high school
d-amino acid oxidase inhibition (daaoi-1) add-on treatment for chronic schizophrenia

Conditions: Schizophrenias; Psychoses; Psychotic Disorders; Schizophrenic Disorders

Summary: adjuvant n-methyl-d-aspartic acid (nmda)-enhancing agents, such as glyt-1 inhibitors and nmda-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia patients. the purpose of this study is to evaluate efficacy and safety of add-on treatment of an inhibitor of d-amino acid oxidase (daaoi), daaoi-1, in chronically stable schizophrenia patients who have been stabilized with antipsychotics.

the etiology of schizophrenia remains unclear. schizophrenia patients reveal positive symptoms, negative symptoms, and cognitive impairments. in addition to dopamine system hyperactivity, hypofunction of n-methyl-d-aspartate (nmda) receptor plays a role in the pathophysiology of schizophrenia. consequently, enhancing nmda receptor neurotransmission has been regarded as a novel treatment approach. to date, several reported trials on adjuvant nmda-enhancing agents, including glycine, d-amino acids (d-serine, d-alanine), and sarcosine (a glycine transporter i inhibitor), revealed beneficial but limited efficacy for positive and negative symptoms. daaoi-1 is a d-amino acid oxidase (daao) inhibitor which can elevate synaptic concentration of d-amino acids. the aim of this project is to examine the efficacy and safety of add-on treatment of daaoi-1 in chronically stable schizophrenia patients who have been stabilized with antipsychotics. in the study, 60 schizophrenic patients are recruited into the 6-week trial and randomly assigned into the two groups (1 gm/ddaaoi-1, or placebo) with a double-blind manner. positive and negative syndrome scale (panss), scales for the assessment of negative symptoms (sans), global assessment of function (gaf), quality of life (qol), hamilton depression rating scale 17(ham-d 17), clinical global impression(cgi)and side effects are evaluated every two weeks during the trial. cognitive function ("7 domains of measurement and treatment research to improve cognition in schizophrenia" \[matrics\])are assessed at weeks 0 and 6. the efficacies of two groups are compared.

Eligibility criteria:
inclusion criteria: * are physically healthy and have all laboratory assessments (including urine/blood routine, biochemical tests, and electrocardiograph) within normal limits * aged 18-65 year * fulfill the criteria of schizophrenia according to the diagnostic and statistical manual, fourth edition (dsm-iv) * remain symptomatic but without clinically significant fluctuation and the antipsychotic doses are unchanged for at least 3 months * have a minimum baseline total score of 60 on the positive and negative syndrome scale (panss) * agree to participate in the study and provide informed consent exclusion criteria: * dsm-iv diagnosis of substance (including alcohol) abuse or dependence, * dsm_iv diagnosis of mental retardation * history of epilepsy, head trauma or cns diseases * history of epilepsy, head trauma or cns diseases * pregnancy or lactation * inability to follow protocol
a study to evaluate the risk of tumor lysis syndrome (tls) in adult participants receiving oral venetoclax in combination with intravenously infused obinutuzumab or oral acalabrutinib for previously untreated chronic lymphocytic leukemia (cll)

Conditions: Chronic Lymphocytic Leukemia

Summary: chronic lymphocytic leukemia (cll) is the most common leukemia (cancer of blood cells). the purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of cll. adverse events and change in disease activity will be assessed. venetoclax in combination with obinutuzumab or acalabrutinib is being investigated in the treatment of cll. study doctors put the participants in 1 of 4 groups, called treatment arms. participants will receive oral venetoclax in combination with intravenously (iv) infused obinutuzumab or oral acalabrutinib at in different dosing schemes as part of treatment. approximately 120 adult participants with cll who are being treated with venetoclax will be enrolled in the study in approximately 80 sites worldwide. participants in arm a will receive oral venetoclax in combination with iv infused obinutuzumab, with a 5 week venetoclax ramp up. participants in arm b will receive oral venetoclax in combination with oral acalabrutinib, with a 5 week venetoclax ramp up. participants in arm c and arm d will receive oral venetoclax in combination with oral acalabrutinib, with differing venetoclax ramp up periods. the total study duration is approximately 28 months. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at a hospital or clinic. the effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.


Eligibility criteria:
inclusion criteria: * diagnosis of documented, previously untreated, chronic lymphocytic leukemia (cll) requiring treatment according to the 2018 international workshop on chronic lymphocytic leukemia (iwcll) criteria and have a life expectancy of \> 6 months. * previously untreated small lymphocytic lymphoma (sll) meeting the 2018 iwcll criteria for treatment will also be equally considered as cll for eligibility, screening, treatment and evaluation. * eastern cooperative oncology group (ecog) performance status \<= 2. * adequate marrow function independent of growth factor or transfusion support within 2 weeks of screening, unless cytopenia is due to marrow involvement of cll as listed in the protocol. * creatinine clearance (crcl) \>= 30 ml/min using the cockcroft-gault formula are eligible for inclusion. exclusion criteria: - active/uncontrolled infection, no richter's transformation, no active immune thrombocytopenia.

Keywords: chronic lymphocytic leukemia cll venetoclax abt-199 obinutuzumab acalabrutinib
study on cognitive disorders of multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to determine if memantine is effective in the treatment on cognitive disorders of relapsing - remitting multiple sclerosis. m


Eligibility criteria:
inclusion criteria: * remitting multiple sclerosis defined by mc donald et al., 2001 * patient with authorised immunomodulator treatment or oral immunosuppressive therapy during more than three months: bétâ interferon, glatiramer acetate, azathioprine, methotrexate, mycophenolate mofetil, treatment by monoclonal antibody i.v. or anti-vla4, natalizumab (tysabri) * patient having benefited, possibly, of following treatments : mitoxantrone, cyclophosphamide, cyclosporine, general-purpose immunoglobulins, only if the treatment is ended more of 6 months before the inclusion. * edss score ≤ 5.5 * drs score ≥ 130 * pasat 3s score \> 15 and \< median / control subjects according to 2 age brackets, sex, school level. * signed the informed consent form. * effective contraception for women in age to procreate exclusion criteria: * progressive form ms * ms relapse of less of 4 weeks. * iv or oral corticoid treatment in the month preceding the screening * medicinal treatments or non medicinal in cognitive or psychology-stimulant aim in the 3 months before the screening * tumoral form ms visible in the mri. * depressive syndrome (madrs score \> 19). * quite other diagnosed psychiatric pathology * known allergy or quite contraindication in memantin : renal or hepatic insufficiency, turned out epileptic disease, treatment by ketamine, amantadin, dextromethorphan, l-dopa, dopaminergic agonist, barbituric, neuroleptic, 3,4-diaminopyridine, lithium, cimetidine, ranitidine, procainamide, quinine, nicotine, hydrochlorthiazide and ally, phenytoin, modafinil. * recent treatment (less of 4 weeks) by antidepressants and/or anxiolytics. * pregnancy or feeding. * minor or major "protected by the law" patient * uncontrolled diet. * patient having benefited of one psychometric assessment(including in particular tests planned in the protocol) since less of one year.
a study of abicipar pegol in patients with diabetic macular edema

Conditions: Macular Edema

Summary: this is a safety and efficacy study of abicipar pegol in patients with diabetic macular edema.


Eligibility criteria:
inclusion criteria: * diagnosis of diabetes mellitus (type 1 or 2) * decreased vision due to diabetic macular edema in at least 1 eye * best corrected visual acuity of 20/32 to 20/320 in the study eye and 20/200 or better in the fellow eye exclusion criteria: * stroke or heart attack within the past 3 months * history of vitrectomy, macular surgery, or glaucoma surgery in the study eye * cataract or refractive surgery in the study eye within the last 3 months * laser photocoagulation of the study eye within the last 3 months